Spontaneous remission of variant angina documented by Holter monitoring and ergonovine testing in patients treated with calcium antagonists

Cardiac arrest and sudden unexpected death in variant angina: complications of coronary spasm that can occur in the absence of severe organic coronary stenosis

Experiences in 81 patients with variant angina were reviewed with the goal of determining which clinical features were associated with the greatest risk of angina-linked cardiac arrest (13 patients) or sudden unexpected death (9 patients). The risk of occurrence of one of these actually or potentially fatal events was approximately tripled by the presence of either a history of angina-linked syncope or documentation of serious arrhythmia complicating attacks. An unexpected finding was that the risk was increased 1.5-fold by the absence of high-grade organic coronary stenosis. Cardiac arrest and sudden death are important risks of variant angina, which can occur without the presence of severe organic coronary stenosis. These risks can be reduced by adequate vasodilator therapy that includes a calcium channel blocker.

Felodipine (once daily) versus nifedipine (four times daily) for Prinzmetal's angina pectoris

In 30 consecutive patients with Prinzmetal's angina pectoris, the antiischemic effect of felodipine, a new long-acting vasoselective calcium antagonist, administered at doses of 10 and 20 mg once daily was compared with that of the well-established therapeutic regimen with nifedipine administered at a dose of 20 mg 4 times daily. Twenty-four-hour Holter monitoring was performed during a 2-day placebo run-in and at the end of each of 3 consecutive 6-day periods during which the 3 active treatments were administered in randomized sequence. Three patients withdrew, whereas 27 completed the study. The therapeutic regimens tested proved to be similarly effective; primary end points (ischemic episodes recorded by Holter monitoring, and anginal attacks reported on diary cards) occurred in 5 patients (19%) during nifedipine treatment, and in 7 (26%) and 3 (11%) during felodipine treatment with 10 and 20 mg, respectively (p = not significant). The distribution of residual ischemic episodes demonstrated that treatment with felodipine once daily provides 24-hour antiischemic protection. Twenty-six patients were followed up with 20 mg of felodipine once daily for a mean of 6 +/- 5 months, and 21 of them (81%) remained free of symptoms and Holter-recorded ischemic attacks. It is concluded that for Prinzmetal's angina pectoris, 24-hour antiischemic protection may be achieved with administration of felodipine once daily. The availability of a simplified therapeutic approach may constitute a real advantage in terms of patient compliance and improving the quality of life.

Ambulatory (Holter) electrocardiography and myocardial ischemia

Ambulatory (Holter) electrocardiography has evolved over the past two decades to allow accurate assessment of the cardiac rhythm, and more recently, accurate detection and measurement of ST segment changes. These ambulatory ECG ST segment changes that occur with and without symptoms, although thought to be of questionable clinical value for many years, have recently been clearly documented in coronary artery disease patients to represent true myocardial ischemia. Concurrent with these technologic developments has been an evolution of the pathophysiologic understanding of myocardial ischemia, and the relative role and sequential nature that ECG ST segment changes have in its development. This review examines from a clinical perspective the current understanding of the pathophysiologic sequence of development of myocardial ischemia, emphasizes the ECG diagnostic methods that detect this sequential change, examines the criteria that define ambulatory ECG myocardial ischemia, and discusses those nonischemic factors that affect the ECG ST segment and its interpretation. Moreover, an ever increasing number of ambulatory ECG studies of coronary artery disease and normal patients have defined unique characteristics of the ambulatory ECG ST segment changes observed with regard to its diagnostic, prognostic, and therapeutic assessment value in the study of myocardial ischemia.

Early evolution of symptoms and long-term prognosis in variant angina: importance of the functional component of coronary arterial disease

PURPOSE

Most investigations describing the long-term outcome of large groups of patients with variant angina pectoris have focused on such endpoints as myocardial infarction, coronary artery surgery, and death, and have asked how the risk of these events is related to the severity of existing organic coronary disease. It is also possible to ask what is the relative importance of organic and functional components in causation of symptoms and outcomes, as was done in this study.

PATIENTS AND METHODS

The early and long-term clinical course was observed in a group of 80 patients with variant angina and a low prevalence of severe organic coronary disease (diameter stenosis greater than 70 percent of one vessel in 28.3 percent, of two or more vessels in 2.7 percent). Patients were seen at the UCLA Medical Center between July 1963 and June 1985.

RESULTS

The following observations were made: Compared with those experiencing a first episode of angina at rest, subjects whose first episode of vasospastic angina occurred during strenuous effort were more likely subsequently to have a positive exercise test result and a more stable but long-term anginal course. A good initial response to vasodilator therapy indicated a likelihood of being alive and symptom-free without an intervening myocardial infarction by five years after diagnosis, which was twice the rate as if initial response to such treatment was poor. The presence or absence of severe coronary artery obstruction as detected by angiography could not be predicted from the nature or severity of angina, the historical presence of effort angina, or the occurrence of a positive result on an exercise test. The existence of severe coronary stenosis in at least one vessel was not associated with an increased incidence of myocardial infarction, cardiac arrest, or death in the first nine years after diagnosis.

CONCLUSION

These findings are consistent with the hypothesis that manifestations of ischemic heart disease in these patients were more directly caused by coronary vasospasm than by the degree of organic coronary obstruction seen by coronary arteriography. In addition, the presence of severe organic stenosis in one coronary artery did not appear to be associated with measurably increased adverse effects on clinical course or survival over the first nine years after diagnosis.

Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials

An analysis of 41 trials of angina of all varieties confirms that calcium antagonists are an important advance and are now established therapy for these syndromes. In effort angina, verapamil in a dose of 360-480 mg daily is better than propranolol in standard doses. Although nifedipine is highly effective against vasospastic angina, its use in threatened myocardial infarction or severe unstable angina is not supported by recent studies, unless combined with a beta-blocker. Diltiazem has recently been tested with apparent benefit in non-Q-wave myocardial infarction. Otherwise, these calcium antagonist agents all seem to have approximate equipotency in clinical ischemic syndromes including effort and vasospastic angina. Subjective side effects seem most troublesome in the case of nifedipine. All three calcium antagonists, especially nifedipine, have been successfully combined with beta-blocker therapy, yet occasional additive negative inotropic or chronotropic or dromotropic interactions may occur when verapamil or diltiazem is added to beta-blockade, and occasionally the direct negative inotropic potential of nifedipine may become evident. The choice between the calcium antagonists is determined not only by the clinical picture but also by the anticipated side effects in a given patient and by the overall cardiovascular status. In patients with supraventricular tachycardias or sinus tachycardia, verapamil or diltiazem is preferred, whereas in patients with a resting bradycardia or borderline heart failure nifedipine is likely to be chosen.